Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients
- Autori: Caffo O.; Frantellizzi V.; Monari F.; Sbrana A.; Costa R.P.; Pinto C.; Tucci M.; Baldari S.; Facchini G.; Bortolus R.; Alongi F.; Alongi P.; Palermo A.; Fanti S.; Biasco E.; Murabito A.; Filice A.; Zichi C.; Pignata S.; Borsatti E.; Salgarello M.; Spada M.; Cortesi E.; Vincentis G.D.
- Anno di pubblicazione: 2021
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/673100
Abstract
Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.